NAPIGEN, Inc. Secures U.S. Patent, Awarded USDA SBIR Grant The USPTO issued a patent to NAPIGEN for the use of CRISPR technologies to edit organellar genomes. Separately, USDA awarded NAPIGEN an SBIR phase 1 grant.